Azetidine-Substituted Pyridines for Selective CB2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective and selective agonists for the Cannabinoid Receptor 2 (CB2) to address a range of human diseases including chronic pain, atherosclerosis, neuroinflammation, ischemia/reperfusion injury, and systemic fibrosis, where the inflammatory response contributes to tissue damage.
Innovation Solution
Development of azetidine-substituted pyridine compounds that selectively bind to and modulate the CB2 receptor, reducing its activity and providing therapeutic benefits in conditions like ischemia/reperfusion injury and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If early CB2 agonist compounds are used, then beneficial effects in pre-clinical models are achieved, but lack of selectivity and effectiveness in human disease treatment remains
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the pyridine core structure. The azetidine ring at position 3, combined with specific substituents at positions 2 and 6, creates localized molecular features that selectively interact with CB2 receptor binding sites, achieving both therapeutic effectiveness and receptor selectivity
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including the type of substituents (halogen, alkyl, aryl groups), their positions on the pyridine ring, and the nature of linkers connecting to the azetidine ring. These parameter variations optimize the balance between therapeutic effectiveness and CB2 selectivity
2Adaptability or versatility
If current therapies are used, then treatment of various diseases is attempted, but effective and selective CB2 agonists are lacking
Solution Approach 1:
The patent achieves universality by designing a pyridine-based agonist scaffold that can effectively treat multiple disease conditions including chronic pain, atherosclerosis, neuroinflammation, ischemia/reperfusion injury, and systemic fibrosis. The core molecular structure maintains consistent CB2 selectivity while addressing diverse pathological conditions through the endocannabinoid system
3Object-affected harmful factors
If CB2 receptor activity is reduced, then inflammatory responses and fibrosis progression are reduced, but CB1 receptor activity may be affected
Solution Approach 1:
The patent converts the potential harm of CB1 receptor side effects into benefit by designing a molecule with high CB2 selectivity. The azetidine-substituted pyridine structure preferentially activates CB2 receptors that mediate anti-inflammatory and anti-fibrotic effects, while the selective profile minimizes activation of CB1 receptors that would cause psychoactive side effects, thus converting the challenge of receptor selectivity into a therapeutic advantage
Data Source
AI summary
The invention relates to a compound of formula (I) wherein A1 and R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament, via inhibition of the cannabinoid receptor 2 (CB2).